NAMS
NewAmsterdam Pharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 3
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
Significant Net Income Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NAMS
Newamsterdam Pharma Company N.V.
A biotechnology company that aims to treat metabolic diseases
Pharmaceutical
10/17/2019
02/08/2021
NASDAQ Stock Exchange
68
12-31
Common stock
Gooimeer 2-35, 1411 DC Naarden, The Netherlands
--
NewAmsterdam Pharma Company N.V. was incorporated as a private limited liability company under the laws of the Netherlands on October 17, 2019 in the name of NewAmsterdam Pharma B.V. NewAmsterdam Pharma changed its name to NewAmsterdam Pharma Holding B.V. in October 2021. They are a clinical-stage biopharmaceutical company developing oral non-statins for high-risk patients with cardiovascular disease (CVD) who have elevated low-density lipoprotein cholesterol (LDL-C or LDL) residues for which existing therapies are not effective or well tolerated. There is a huge unmet need for an effective, cost-effective and convenient low-density lipoprotein reduction therapy as an adjunct to statins. Statins are currently the standard of care for patients with high cholesterol and high risk CVD. Their lead product candidate, obicetrapib, is a next-generation oral low-dose cholesterol ester transfer protein (CETP) inhibitor currently in four Phase 3 and Phase 2 b clinical trials as monotherapy and ezetimibe combination therapy for lowering LDL-C and preventing major cardiovascular adverse events (" MACE ").
Company Financials
EPS
NAMS has released its 2025 Q3 earnings. EPS was reported at -0.61, versus the expected -0.403865, missing expectations. The chart below visualizes how NAMS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NAMS has released its 2025 Q3 earnings report, with revenue of 348.00K, reflecting a YoY change of -98.80%, and net profit of -72.00M, showing a YoY change of -332.54%. The Sankey diagram below clearly presents NAMS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
